Since 2013, Mark Moshayedi has functioned as the CEO of MSM Global Ventures, an investment firm in Newport Beach, California. Committed to philanthropic undertakings outside of work, Mark Moshayedi donates to several higher learning and health care-related institutions, including the American Cancer Society (ACS).
One of the key goals of the ACS is driving groundbreaking research in cancer detection and treatment. Recently, researchers funded by the organization made a discovery that could lead to new approaches to lung cancer treatment.
The human genome contains much DNA that does not code for proteins, which has largely been viewed as “junk DNA.” However, the research found that a non-coding gene known as microRNA-31 could play a role in the development of lung cancer.
The researchers demonstrated that the gene could cause the cells lining an organ to become cancerous. More than three-fourths of lung cancer patients have increased expression levels of this gene. The next step in the study is to examine whether removing the gene affects lung cancer tumor growth.
Targeting microRNA-31 could lead to exciting new lung cancer treatments, which is especially important considering that lung cancer remains the leading cause of cancer death in men and women.
Comments
Post a Comment